Design in the cloud

BELFAST, Northern Ireland—In mid-June, data analysis and clinical trial software specialist company Exploristics announced plans to launch an updated version of its cloud-based data analytics platform for clinical trial design, KerusCloud 2.0. Plans at the time called for release by the end of the summer.

The software offers what the company calls “unique second-generation simulation capabilities, providing a virtual environment for optimizing clinical study design and data analysis through the processing power of cloud computing.”

First launched in 2018, KerusCloud is currently the only software available that can simulate trials with multiple correlated outcomes, according to Exploristics, allowing it “to untangle the complex relationships between the many biological factors that can influence a study’s outcome. Its cloud-based approach makes the simulation of complex studies an affordable and accessible option regardless of project size.”

KerusCloud 2.0 builds on its previous incarnation by reportedly enabling more realistic clinical trial simulations thanks to a new feature that generates correlated data for sub-groups within a patient population, facilitating the investigation of precision medicine or adaptive development pathways. This means that clusters of patients in a clinical trial grouped by factors such as genetics, risk factors and biological subtypes can be looked at in greater detail, enabling clinical development teams to pursue more complex clinical strategies with in-silico design tools.

The latest version also delivers an enhanced user experience with simulations that are said to be 96 times faster, allowing users to explore a greater range of options in a much shorter time period. In addition, increased security features have been added, such as multi-factor authentication.

“We’ve already witnessed the profound difference KerusCloud can make to our customers’ clinical trials, with one customer saving $25 million and three years development time in their clinical development strategy,” said Dr. Aiden Flynn, CEO of Exploristics. “The updated KerusCloud 2.0 puts clinical development teams at the forefront of complex study design supporting key decision-making to optimize and accelerate clinical development strategies.”

To support KerusCloud 2.0, Exploristics will be offering enhanced consulting services with a dedicated team of experts available to help ensure that customers can reap the full benefit of the new version as they confront the challenges of increasingly complex clinical scenarios.

Continued Flynn: “Removing barriers to state-of-the-art clinical trial planning is vital to transforming global clinical practice and improving the quality of clinical research, and we believe KerusCloud 2.0 will play a key role in that.”

The platform has even caught the attention of the government, with Exploristics recently awarded a £1-million Innovate UK loan to extend its capabilities by integrating it into an intelligent software ecosystem.